Journal of Vascular Surgery
Volume 45, Issue 6, Supplement , Pages A64-A73 , June 2007

The role of nitric oxide in the pathophysiology of intimal hyperplasia

Received 18 January 2007 ,Accepted 11 February 2007.

References 

  1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373–376
  2. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524–526
  3. Bredt DS, Snyder SH. Nitric oxide: a physiologic messenger molecule. Annu Rev Biochem. 1994;63:175–195
  4. Ignarro LJ, Lippton H, Edwards JC, Baricos WH, Hyman AL, Kadowitz PJ, et al. Mechanism of vascular smooth-muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric-oxide - evidence for the involvement of s-nitrosothiols as active intermediates. J Pharmacol Exp Ther. 1981;218:739–749
  5. Arnold WP, Mittal CK, Katsuki S, Murad F. Nitric-oxide activates guanylate cyclase and increases guanosine 3’-5’-cyclic monophosphate levels in various tissue preparations. Proc Natl Acad Sci U S A. 1977;74:3203–3207
  6. Furchgott RF. Introduction to EDRF research. J Cardiovasc Pharmacol. 1993;22:S1–S2
  7. Ignarro LJ, Cirino G, Casini A, Napoli C. Nitric oxide as a signaling molecule in the vascular system: An overview. J Cardiovasc Pharmacol. 1999;34:879–886
  8. Murad F, Rapoport RM, Fiscus R. Role of cyclic-GMP in relaxations of vascular smooth muscle. J Cardiovasc Pharmacol. 1985;7(suppl 3):S111–S118
  9. Forstermann U, Closs EI, Pollock JS, Nakane M, Schwarz P, Gath I, et al. Nitric oxide synthase isozymes (Characterization, purification, molecular cloning, and functions). Hypertension. 1994;23:1121–1131
  10. Morris SMJ, Billiar TR. New insights into the regulation of inducible nitric oxide synthesis. Am J Physiol. 1994;266:E829–E839
  11. Nathan C, Xie QW. Nitric oxide synthases: roles, tolls, and controls. Cell. 1994;78:915–918
  12. Clowes AW, Reidy MA, Clowes MM. Mechanisms of stenosis after arterial injury. Lab Invest. 1983;49:208–215
  13. Fingerle J, Johnson R, Clowes AW, Majesky MW, Reidy MA. Role of platelets in smooth muscle cell proliferation and migration after vascular injury in rat carotid artery. Proc Natl Acad Sci U S A. 1989;86:8412–8416
  14. Ross R. Atherosclerosis—a problem of the biology of arterial-wall cells and their interactions with blood components. Arteriosclerosis. 1981;1:293–311
  15. Ross R, Glomset J, Kariya B, Harker L. Platelet-dependent serum factor that stimulates proliferation of arterial smooth-muscle cells in vitro. Proc Natl Acad Sci U S A. 1974;71:1207–1210
  16. Mitra AK, Del Core MG, Agrawal DK. Cells, cytokines and cellular immunity in the pathogenesis of fibroproliferative vasculopathies. Can J Physiol Pharmacol. 2005;83:701–715
  17. Ross R, Raines EW, Bowenpope DF. The biology of platelet-derived growth-factor. Cell. 1986;46:155–169
  18. Libby P, Warner SJ, Friedman GB. Interleukin-1: a mitogen for human vascular smooth-muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest. 1988;81:487–498
  19. Yang J, Ji RR, Cheng YH, Zhang CX. A novel model of inflammatory neointima formation reveals a role of myeloperoxidase in neointimal hyperplasia. Arterioscler Thromb Vasc Biol. 2006;26:E71–E72
  20. Baldus S, Rudolph V, Roiss M, Ito WD, Rudolph TK, Eiserich JP, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation. 2006;113:1871–1878
  21. Lindner V, Lappi DA, Baird A, Majack RA, Reidy MA. Role of basic fibroblast growth factor in vascular lesion formation. Circ Res. 1991;68:106–113
  22. Clowes AW, Clowes MM, Reidy MA. Kinetics of cellular proliferation after arterial injury (III. Endothelial and smooth muscle growth in chronically denuded vessels). Lab Invest. 1986;54:295–303
  23. Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol. 2006;69:1527–1533
  24. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539–545
  25. Hasenstab D, Forough R, Clowes AW. Plasminogen activator inhibitor type 1 and tissue inhibitor of metalloproteinases-2 increase after arterial injury in rats. Circ Res. 1997;80:490–496
  26. Majesky MW, Lindner V, Twardzik DR, Schwartz SM, Reidy MA. Production of transforming growth factor beta 1 during repair of arterial injury. J Clin Invest. 1991;88:904–910
  27. Nabel EG, Shum L, Pompili VJ, Yang ZY, San H, Shu HB, et al. Direct transfer of transforming growth factor beta 1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci U S A. 1993;90:10759–10763
  28. Anderson PG, Boerth NJ, Liu M, McNamara DB, Cornwell TL, Lincoln TM. Cyclic GMP-dependent protein kinase expression in coronary arterial smooth muscle in response to balloon catheter injury. Arterioscler Thromb Vasc Biol. 2000;20:2192–2197
  29. Lindner V, Majack RA, Reidy MA. Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest. 1990;85:2004–2008
  30. Rudic RD, Shesely EG, Maeda N, Smithies O, Segal SS, Sessa WC. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest. 1998;101:731–736
  31. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. [see comments] Nature. 1995;377:239–242
  32. Zhang LN, Wilson DW, da Cunha V, Sullivan ME, Vergona R, Rutledge JC, et al. Endothelial NO synthase deficiency promotes smooth muscle progenitor cells in association with upregulation of stromal cell-derived factor-1 alpha in a mouse model of carotid artery ligation. Arterioscler Thromb Vasc Biol. 2006;26:765–772
  33. Fischer JW, Hawkins S, Clowes AW. Pharmacologic inhibition of nitric oxide synthases and cyclooxygenases enhances intimal hyperplasia in balloon-injured rat carotid arteries. J Vasc Surg. 2004;40:115–122
  34. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987;2:1057–1058
  35. Yan ZQ, Yokota T, Zhang W, Hansson GK. Expression of inducible nitric oxide synthase inhibits platelet adhesion and restores blood flow in the injured artery. Circ Res. 1996;79:38–44
  36. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A. 1991;88:4651–4655
  37. Hickey MJ, Sharkey KA, Sihota EG, Reinhardt PH, Macmicking JD, Nathan C, et al. Inducible nitric oxide synthase-deficient mice have enhanced leukocyte-endothelium interactions in endotoxemia. FASEB J. 1997;11:955–964
  38. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 1989;83:1774–1777
  39. Sarkar R, Gordon D, Stanley JC, Webb RC. Cell cycle effects of nitric oxide on vascular smooth muscle cells. Am J Physiol. 1997;272:H1810–H1818
  40. Ishida A, Sasaguri T, Kosaka C, Nojima H, Ogata J. Induction of the cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1) by nitric oxide-generating vasodilator in vascular smooth muscle cells. J Biol Chem. 1997;272:10050–10057
  41. Kibbe MR, Li J, Nie S, Watkins SC, Lizonova A, Kovesdi I, et al. Inducible nitric oxide synthase (iNOS) expression upregulates p21 and inhibits vascular smooth muscle cell proliferation through p42/44 mitogen-activated protein kinase activation and independent of p53 and cyclic guanosine monophosphate. J Vasc Surg. 2000;31:1214–1228
  42. Tanner FC, Meier P, Greutert H, Champion C, Nabel EG, Luscher TF. Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Circulation. 2000;101:1982–1989
  43. Dubey RK, Jackson EK, Luscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell (Role of cyclic-nucleotides and angiotensin1 receptors). J Clin Invest. 1995;96:141–149
  44. Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res. 1996;78:225–230
  45. Pollman MJ, Yamada T, Horiuchi M, Gibbons GH. Vasoactive substances regulate vascular smooth muscle cell apoptosis - Countervailing influences of nitric oxide and angiotensin II. Circ Res. 1996;79:748–756
  46. Nishio E, Fukushima K, Shiozaki M, Watanabe Y. Nitric oxide donor SNAP induces apoptosis in smooth muscle cells through cGMP-independent mechanism. Biochem Biophys Res Commun. 1996;221:163–168
  47. Iwashina M, Shichiri M, Marumo F, Hirata Y. Transfection of inducible nitric oxide synthase gene causes apoptosis in vascular smooth muscle cells. Circulation. 1998;98:1212–1218
  48. Gurjar MV, Sharma RV, Bhalla RC. eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity. Arterioscler Thromb Vasc Biol. 1999;19:2871–2877
  49. Dupuis M, Soubrier F, Brocheriou I, Raoux S, Haloui M, Louedec L, et al. Profiling of aortic smooth muscle cell gene expression in response to chronic inhibition of nitric oxide synthase in rats. Circulation. 2004;110:867–873
  50. Chaux A, Ruan XM, Fishbein MC, Ouyang Y, Kaul S, Pass JA, et al. Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation. J Thorac Cardiovasc Surg. 1998;115:604–612
  51. Dattilo JB, Dattilo MPM, Crane JT, Yager DR, Makhoul RG. The nitric oxide precursor L-arginine reduces expression of hyaluronan synthase in experimental vein bypass grafts. J Surg Res. 1998;74:39–42
  52. Schmidt A, Geigenmueller S, Voelker W, Seiler P, Buddecke E. Exogenous nitric oxide causes overexpression of TGF-beta(1) and overproduction of extracellular matrix in human coronary smooth muscle cells. Cardiovas Res. 2003;58:671–678
  53. Rizvi MAD, Myers PR. Nitric oxide modulates basal and endothelin-induced coronary artery vascular smooth muscle cell proliferation and collagen levels. J Mol Cell Cardiol. 1997;29:1779–1789
  54. Kolpakov V, Gordon D, Kulik TJ. Nitric oxide-generating compounds inhibit total protein and collagen-synthesis in cultured vascular smooth-muscle cells. Circ Res. 1995;76:305–309
  55. Guo JP, Panday MM, Consigny PM, Lefer AM. Mechanisms of vascular preservation by a novel NO donor following rat carotid artery intimal injury. Am J Physiol. 1995;269:H1122–H1131
  56. Milkiewicz M, Ispanovic E, Doyle JL, Haas TL. Regulators of angiogenesis and strategies for their therapeutic manipulation. Int J Biochem Cell Biol. 2006;38:333–357
  57. Parenti A, Morbidelli L, Cui XL, Douglas JG, Hood JD, Granger HJ, et al. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase1/2 activation in postcapillary endothelium. J Biol Chem. 1998;273:4220–4226
  58. Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA, et al. Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest. 1994;94:2036–2044
  59. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest. 1997;99:2625–2634
  60. Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998;101:2567–2578
  61. RayChaudhury A, Frischer H, Malik AB. Inhibition of endothelial cell proliferation and bFGF-induced phenotypic modulation by nitric oxide. J Cell Biochem. 1996;63:125–134
  62. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, et al. Nitric oxide synthase mediates vascular endothelial growth factor but not basic fibroblast growth factor induced angiogenesis. FASEB J. 1997;11:1137
  63. Dimmeler S, Haendeler J, Nehls M, Zeiher AM. Suppression of apoptosis by nitric oxide via inhibition of interleukin- 1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)- 32-like proteases. J Exp Med. 1997;185:601–607
  64. Tzeng E, Kim YM, Pitt BR, Lizonova A, Kovesdi I, Billiar TR. Adenoviral transfer of the inducible nitric oxide synthase gene blocks endothelial cell apoptosis. Surgery. 1997;122:255–263
  65. DeMeester SL, Qiu YY, Buchman TG, Hotchkiss RS, Dunnigan K, Karl IE, et al. Nitric oxide inhibits stress-induced endothelial cell apoptosis. Crit Care Med. 1998;26:1500–1509
  66. Lee JS, Adrie C, Jacob HJ, Roberts JDJ, Zapol WM, Bloch KD. Chronic inhalation of nitric oxide inhibits neointimal formation after balloon-induced arterial injury. Circ Res. 1996;78:337–342
  67. McNamara DB, Bedi B, Aurora H, Tena L, Ignarro LJ, Kadowitz PJ, et al. L-arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem Biophys Res Commun. 1993;193:291–296
  68. Chen C, Mattar SG, Lumsden AB. Oral administration of L-arginine reduces intimal hyperplasia in balloon-injured rat carotid arteries. J Surg Res. 1999;82:17–23
  69. Groves PH, Banning AP, Penny WJ, Newby AC, Cheadle HA, Lewis MJ. The effects of exogenous nitric oxide on smooth muscle cell proliferation following porcine carotid angioplasty. Cardiovasc Res. 1995;30:87–96
  70. Lablanche JM, Grollier G, Lusson JR, Bassand JP, Drobinski G, Bertrand B, et al. Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty (The ACCORD Study. Angioplastic Coronaire Corvasal Diltiazem). Circulation. 1997;95:83–89
  71. Napoli C, Cirino G, Del Soldato P, Sorrentino R, Sica V, Condorelli M, et al. Effects of nitric oxide-releasing aspirin versus aspirin on restenosis in hypercholesterolemic mice. Proc Natl Acad Sci U S A. 2001;98:2860–2864
  72. Wohrle J, Hoher M, Nusser T, Hombach V, Kochs M. No effect of highly dosed nitric oxide donor molsidomine on the angiographic restenosis rate after percutaneous coronary angioplasty: a randomized, placebo controlled, double-blind trial. Can J Cardiol. 2003;19:495–500
  73. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, et al Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci U S A. 1995;92:1137–1141
  74. Chen L, Daum G, Forough R, Clowes M, Walter U, Clowes AW. Overexpression of human endothelial nitric oxide synthase in rat vascular smooth muscle cells and in balloon-injured carotid artery. Circ Res. 1998;82:862–870
  75. Janssens S, Flaherty D, Nong Z, Varenne O, Van Pelt N, Haustermans C, et al. Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats. Circulation. 1998;97:1274–1281
  76. Varenne O, Pislaru S, Gillijns H, Van Pelt N, Gerard RD, Zoldhelyi P, et al. Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs. Circulation. 1998;98:919–926
  77. Shears LL, Kibbe MR, Murdock AD, Billiar TR, Lizonova A, Kovesdi I, et al. Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo. J Am Coll Surg. 1998;187:295–306
  78. Kibbe MR, Tzeng E, Gleixner SL, Watkins SC, Kovesdi I, Lizonova A, et al. Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia. J Vasc Surg. 2001;34:156–165
  79. Wang K, Kessler PD, Forudi F, Zhou Z, Zhou X, Tarakji K, et al. Local adenoviral-mediated inducible nitric oxide synthase (iNOS) gene transfer inhibits neointimal formation in the porcine coronary stented model. Am J Cardiol. 2001;88:51G–52G
  80. Marks DS, Vita JA, Folts JD, Keaney JFJ, Welch GN, Loscalzo J. Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. J Clin Invest. 1995;96:2630–2638
  81. Schwarzacher SP, Lim TT, Wang BY, Kernoff RS, Niebauer J, Cooke JP, et al. Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty. Circulation. 1997;95:1863–1869
  82. Fulton GJ, Davies MG, Barber L, Gray JL, Svendsen E, Hagen PO. Local effects of nitric oxide supplementation and suppression in the development of intimal hyperplasia in experimental vein grafts. Eur J Vasc Endovasc Surg. 1998;15:279–289
  83. Kaul S, Cercek B, Rengstrom J, Xu XP, Molloy MD, Dimayuga P, et al. Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB. J Am Coll Cardiol. 2000;35:493–501
  84. Harnek J, Zoucas E, Sjuve R, Arner A, Ekblad E, Schou H, et al. Local infusion of the nitric oxide donor SIN-1 after angioplasty: effects on intimal hyperplasia in porcine coronary arteries. Acta Radiol. 2003;44:395–402
  85. Yoon J, Wu CJ, Homme J, Tuch RJ, Wolff RG, Topol EJ, et al. Local delivery of nitric oxide from an eluting stent to inhibit neointimal thickening in a porcine coronary injury model. Yonsei Med J. 2002;43:242–251
  86. Do YS, Kao EY, Ganaha F, Minamiguchi H, Sugimoto K, Lee J, et al. In-stent restenosis limitation with stent-based controlled-release nitric oxide: initial results in rabbits. Radiology. 2004;230:377–382
  87. Hou DM, Narciso H, Kamdar K, Zhang P, Barclay B, March KL. Stent-based nitric oxide delivery reducing neointimal proliferation in a porcine carotid overstretch injury model. Cardiovasc Intervent Radiol. 2005;28:60–65
  88. Rich GF, Roos CM, Anderson SM, Urich DC, Daugherty MO, Johns RA. Inhaled nitric-oxide: dose-response and the effects of blood in the isolated rat lung. J Appl Physiol. 1993;75:1278–1284
  89. Cooney R, Hynes SO, Duffy AM, Sharif F, O’Brien T. Adenoviral-mediated gene transfer of nitric oxide synthase isoforms and vascular cell proliferation. J Vasc Res. 2006;43:462–472
  90. Kown MH, Yamaguchi A, Jahncke CL, Miniati D, Murata S, Grunenfelder J, et al. L-arginine polymers inhibit the development of vein graft neointimal hyperplasia. J Thorac Cardiovasc Surg. 2001;121:971–980
  91. Rolland PH, Mekkaoui C, Palassi M, Friggi A, Moulin G, Piquet P, et al. Efficacy of local molsidomine delivery from a hydrogel-coated angioplasty balloon catheter in the atherosclerotic porcine model. Cardiovasc Intervent Radiol. 2003;26:65–72
  92. Verma S, Marsden PA. Nitric oxide-eluting polyurethanes–vascular grafts of the future?. N Engl J Med. 2005;353:730–731
  93. Smith DJ, Chakravarthy D, Pulfer S, Simmons ML, Hrabie JA, Citro ML, et al. Nitric oxide-releasing polymers containing the [N(O)NO]- group. J Med Chem. 1996;39:1148–1156
  94. Zhang H, Annich GM, Miskulin J, Osterholzer K, Merz SI, Bartlett RH, et al. Nitric oxide releasing silicone rubbers with improved blood compatibility: preparation, characterization, and in vivo evaluation. Biomaterials. 2002;23:1485–1494
  95. Batchelor MM, Reoma SL, Fleser PS, Nuthakki VK, Callahan RE, Shanley CJ, et al. More lipophilic dialkyldiamine-based diazeniumdiolates: synthesis, characterization, and application in preparing thromboresistant nitric oxide release polymeric coatings. J Med Chem. 2003;46:5153–5161
  96. Fleser PS, Nuthakki VK, Malinzak LE, Callahan RE, Seymour ML, Reynolds MM, et al. Nitric oxide-releasing biopolymers inhibit thrombus formation in a sheep model of arteriovenous bridge grafts. J Vasc Surg. 2004;40:803–811
  97. Jun HW, Taite LJ, West JL. Nitric oxide-producing polyurethanes. Biomacromolecules. 2005;6:838–844
  98. Bohl KS, West JL. Nitric oxide-generating polymers reduce platelet adhesion and smooth muscle cell proliferation. Biomaterials. 2000;21:2273–2278
  99. Gappa-Fahlenkamp H, Duan X, Lewis RS. Analysis of immobilized L-cysteine on polymers. J Biomed Mater Res A. 2004;71:519–527
  100. Oh BK, Meyerhoff ME. Catalytic generation of nitric oxide from nitrite at the interface of polymeric films doped with lipophilic Cu(Il)-complex: a potential route to the preparation of thromboresistant coatings. Biomaterials. 2004;25:283–293

 Competition of interest: Dr Kibbe is a paid carotid stenting proctor for Abbott.

PII: S0741-5214(07)00313-8

doi: 10.1016/j.jvs.2007.02.027

Journal of Vascular Surgery
Volume 45, Issue 6, Supplement , Pages A64-A73 , June 2007

Article Tools

* Image Usage & Resolution